Quoin Pharmaceuticals has secured $50.0M in a new funding round, backed by a syndicate that includes Sirenia Capital Management, Sphera Healthcare, AIGH Capital Management, Nantahala Capital, StemPoint Capital, and Stonepine Capital.
The specialty pharmaceutical company, founded in 2018, is focused on developing treatments for rare and orphan diseases. Its pipeline targets conditions like Netherton Syndrome, Peeling Skin Syndrome, and Epidermolysis Bullosa, with plans to build out a sales infrastructure for the U.S. and European markets while pursuing licensing partnerships elsewhere.

















